Zosano Pharma Corp

Zosano Pharma — Investor Presentation (November 2015)

28 slides from Zosano Pharma's investor presentation, Nov 16, 2015

  1. Slide 1: Corporate Presentation November 2015

    Corporate Presentation November 2015 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward‐looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding our commercialization, our research and other development programs, our ability to undertake certai

  3. Slide 3: Zosano Pharma Drug Delivery System: Convenient and Easy-to-Use

    Zosano Pharma Drug Delivery System Convenient and Easy-to-Use :

  4. Slide 4: Zosano approach provides rapid onset

    Zosano approach provides rapid onset Hydrophilic drug formulation coated on tips of microneedles Microneedles are 200-350 microns long – close proximity to capillary bed Formulation quickly dissolved by interstitial fluid for short Tmax Rapid Onset and High Bioavailability Zosano Pharma Drug Deliver

  5. Slide 5: Formulations Stable at Room Temperature

    Zosano Pharma Drug Delivery System Formulations Stable at Room Temperature Higher product stability, longer shelf life vs. injectables requiring refrigeration Dry, hydrophilic formulation of ZP-PTH more stable than Forteo liquid injectables Packaging purged with nitrogen – no moisture or oxygen ensu

  6. Slide 6: Broad ZP-Patch Compatibility Across Molecule Types

    Broad ZP-Patch Compatibility Across Molecule Types Rapid Onset Significant Criterion for Molecule Prioritization Technical Feasibility With 30+ Compounds Screening Criteria Prioritized for Development Weekly ZP-PTH ZP-Glucagon ZP-Triptan Rapid onset provides therapeutic advantage High price per unit

  7. Slide 7: Investment Highlights

    Zosano Pharma (ZSAN) Differentiated transdermal microneedle ZP-Patch delivery platform Capable of delivering small molecules, peptides/proteins and vaccines Fast onset with short Tmax: injection-comparable or better Convenient and easy-to-use: room temperature stable, portable Well validated pipelin

  8. Slide 8: ZP-Triptan for Migraine

    ZP-Triptan for Migraine Phase 1 PK and safety study data released Nov 2015 Potentially best-in-class product with rapid onset Comparable or better onset of action than existing triptans/injectables Self-administration provides significant advantage vs. injectables Large, growing market with attracti

  9. Slide 9: Rapid Onset Associated with Pain Relief

    Rapid Onset Associated with Pain Relief ZP-Triptan With Potential Best-in-Class Onset of Action Products Included: (1) Nasal: Imitrex (sumatriptan), Zomig (zolmitriptan) Oral—Melt: Zomig-ZMT (zolmitriptan) Maxalt-MLT (rizatriptan) (2) Oral—Tablets: Imitrex (sumatriptan), Treximet (sumatriptan/naprox

  10. Slide 10: ZP-Triptan Phase 1 Study

    ZP-Triptan Phase 1 Study Well-tolerated, Achieved Rapid Absorption with Potential for Fast Relief Objective: evaluate tolerability and pharmacokinetics of the ZP-Triptan patch Design: Crossover study among 20 healthy volunteers (five doses of ZP-Triptan, oral administration of zolmitriptan, a subcut

  11. Slide 11: ZP-Glucagon for Severe Hypoglycemia

    ZP-Glucagon for Severe Hypoglycemia Severe hypoglycemia is life-threatening, requiring emergency rescue Ease-of-use critical for third-party caregivers who may lack medical training Rapid onset important for fast recovery Underpenetrated market generates ~$220 million in WW sales Only two glucagon p

  12. Slide 12: Current Products Not User-Friendly vs Zosano Solution

    Complex, multi-step reconstitution, third party administered Significant prep time Press-and-Apply pre-loaded disposable system Fast, simple, no prep needed Unstable formulation Stable, dry patch formulation Short shelf life after reconstitution No reconstitution required Treatment Time Critical for

  13. Slide 13: Formulation Stability a Significant Competitive Advantage

    Formulation Stability a Significant Competitive Advantage Stability Demonstrated at 40° C over Six Months

  14. Slide 14: Phase 1 Clinical Trial Design

    Objective: evaluate safety, tolerability, PK and PD of ZP-Glucagon patch doses of 0.5 mg compared to IM injection of 0.5 mg Design: single-center, open-label, randomized five-way crossover study Testing Regimens: 0.5 mg of ZP-Glucagon Formulation “C” (abdomen) 0.5 mg of ZP-Glucagon Formulation “C” (

  15. Slide 15: Phase 1 PK Data vs. Injection

    20 subjects tested in five-way crossover study Phase 1 PK Data vs. Injection pg/ml A: Patch formulation C / abdomen B: Patch formulation C / forearm C: Patch formulation C / upper arm D: Patch formulation D / abdomen E: Glucagon IM injection Note: AUC measured in ng*hr/mL Short Tmax, High Bioavailab

  16. Slide 16: Phase 1 Glucose Data vs. Injection

    Phase 1 Glucose Data vs. Injection mmol/l A: Patch formulation C / abdomen B: Patch formulation C / forearm C: Patch formulation C / upper arm D: Patch formulation D / abdomen E: Glucagon IM injection All Patch Doses With Comparable PD to Injection

  17. Slide 17: Phase 2 Clinical Trial Summary

    Objective: evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic (glucose) of a single treatment of ZP-Glucagon patches at doses of up to 1 mg compared to IM injection in an insulin-induced hypoglycemia setting Design: multi-center, open-label, randomized four-way crossover study T

  18. Slide 18: Glucagon Promotes Rapid Glucose Response: Full Time Course

    Glucagon Promotes Rapid Glucose Response Full Time Course Glucagon PK Curve Glucagon AUC Glucagon Tmax Glucose Change from Baseline FASTER PATCH TMAX VS. IM INJECTION ZP-Glucagon 0.5 MG ZP-Glucagon 1.0 MG Glucagon IM 0.5 MG Glucagon IM 0.5 MG 0.5 MG OF GLUCAGON IS ABOVE DOSE-RESPONSE CURVE, EVEN WIT

  19. Slide 19: Glucagon Promotes Rapid Glucose Response: First Minutes

    Glucagon Promotes Rapid Glucose Response First 30 Minutes Glucagon PK Curve Glucagon AUC Glucose Change from Baseline ZP-Glucagon 0.5 MG ZP-Glucagon 1.0 MG Glucagon IM 0.5 MG Glucagon IM 0.5 MG Glucagon Tmax 100% RESPONDER RATE 0.5 MG PATCH ACHIEVES COMPARABLE AUC TO 1.0 MG IM

  20. Slide 20: Phase 2 Findings

    Both ZP-Glucagon patch doses normalized blood sugar in 100 percent of the subjects (100% responder rate) Both patch doses achieved rapid onset of action Time to glucose response was similar when comparing ZP-Glucagon patch to IM All treatments were well tolerated and no new safety issues were identi

  21. Slide 21: Weekly ZP-PTH for Osteoporosis

    Forteo (PTH 1-34) is only anabolic in U.S. market with $1.3 billion in worldwide revenue 20 µg daily subcutaneous injection requiring refrigeration and carrying a black box warning with a two-year lifetime limitation on treatment Zosano patch technology tested extensively with PTH molecule (1-34) Co

  22. Slide 22: ZP-PTH Phase 2 Daily Results

    165 patients, daily administration for 6 months, >20,000 patch applications Achieved dose proportionate and pulsatile pharmacokinetics Variability in patch doses comparable to Forteo injectable Higher Hip BMD Gains vs. Forteo Patch Delivered Rapid Onset in Large Study

  23. Slide 23: Weekly PTH Product Currently Marketed by Asahi in Japan

    Asahi’s 56.5mcg weekly PTH reduced vertebral fracture rates by 79% Lower dose 28.2mcg weekly PTH reduced spine fractures by 66% based on a post-hoc analysis of the study data 2-year rat study observed no carcinogenicity at up to 40.7 µg/kg Weekly PTH Product Currently Marketed by Asahi in Japan Phas

  24. Slide 24: Weekly ZP-PTH Patch Program Phase 1 PK Profile

    Source: [add paper citations] Robust Eight-Way Crossover with 32 Patients Demonstrated Pulsatile PK & No Safety Concerns Weekly ZP-PTH Patch Program – Phase 1 PK Profile

  25. Slide 25: ZP-Patch Intellectual Property

    ZP-Patch Intellectual Property Issued Patents (owned & licensed) = 22 US, 12 EU, 13 JP Patent Protection Until 2027 ZP Technology Platform Transdermal & PTH Formulation/ Coating/PK/PD 7 US, 3 EU, 5 JP Micro Projection Design & Anchoring to Skin 4 US, 2 EU, 2 JP Patch Applicator 5 US, 4 EU, 3 JP Reta

  26. Slide 26: Financial Highlights

    Financial Highlights 1. Cash and cash equivalents balance, debt, and shares outstanding as of December 31, 2014, do not reflect the proceeds received, debt converted to equity, and shares issued in connection with the company's January 2015 IPO and concurrent private placement. in millions Q3 2015 Q

  27. Slide 27: Investment Highlights

    Zosano Pharma (ZSAN) Differentiated transdermal microneedle ZP-Patch delivery platform Capable of delivering small molecules, peptides/proteins and vaccines Fast onset with short Tmax: injection-comparable or better Convenient and easy-to-use: room temperature stable, portable Well validated pipelin

  28. Slide 28: Corporate Presentation November 2015

    Corporate Presentation November 2015

Zosano Pharma — Investor Presentation (November 2015) on 6ix